Literature DB >> 21245385

Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression.

Guillermo de Cárcer1, Beatriz Escobar, Alonso M Higuero, Laura García, Alejandra Ansón, Gema Pérez, Manuela Mollejo, Gerard Manning, Bárbara Meléndez, José Abad-Rodríguez, Marcos Malumbres.   

Abstract

Polo-like kinases (Plks) are characterized by the presence of a specific domain, known as the polo box (PBD), involved in protein-protein interactions. Plk1 to Plk4 are involved in centrosome biology as well as the regulation of mitosis, cytokinesis, and cell cycle checkpoints in response to genotoxic stress. We have analyzed here the new member of the vertebrate family, Plk5, a protein that lacks the kinase domain in humans. Plk5 does not seem to have a role in cell cycle progression; in fact, it is downregulated in proliferating cells and accumulates in quiescent cells. This protein is mostly expressed in the brain of both mice and humans, and it modulates the formation of neuritic processes upon stimulation of the brain-derived neurotrophic factor (BDNF)/nerve growth factor (NGF)-Ras pathway in neurons. The human PLK5 gene is significantly silenced in astrocytoma and glioblastoma multiforme by promoter hypermethylation, suggesting a tumor suppressor function for this gene. Indeed, overexpression of Plk5 has potent apoptotic effects in these tumor cells. Thus, Plk5 seems to have evolved as a kinase-deficient PBD-containing protein with nervous system-specific functions and tumor suppressor activity in brain cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245385      PMCID: PMC3067912          DOI: 10.1128/MCB.00607-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  63 in total

1.  Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces Golgi fragmentation.

Authors:  Inmaculada López-Sánchez; Marta Sanz-García; Pedro A Lazo
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

2.  Activity-induced Polo-like kinase 2 is required for homeostatic plasticity of hippocampal neurons during epileptiform activity.

Authors:  Daniel P Seeburg; Morgan Sheng
Journal:  J Neurosci       Date:  2008-06-25       Impact factor: 6.167

3.  Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.

Authors:  María J Bueno; Ignacio Pérez de Castro; Marta Gómez de Cedrón; Javier Santos; George A Calin; Juan C Cigudosa; Carlo M Croce; José Fernández-Piqueras; Marcos Malumbres
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

4.  Activation of Polo-like kinase 3 by hypoxic stresses.

Authors:  Ling Wang; Jie Gao; Wei Dai; Luo Lu
Journal:  J Biol Chem       Date:  2008-07-23       Impact factor: 5.157

Review 5.  Emerging cancer therapeutic opportunities by inhibiting mitotic kinases.

Authors:  Ignacio Pérez de Castro; Guillermo de Cárcer; Guillermo Montoya; Marcos Malumbres
Journal:  Curr Opin Pharmacol       Date:  2008-07-30       Impact factor: 5.547

6.  Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain.

Authors:  Onur Cizmecioglu; Silke Warnke; Marc Arnold; Stefan Duensing; Ingrid Hoffmann
Journal:  Cell Cycle       Date:  2008-11-26       Impact factor: 4.534

Review 7.  Polo-like kinase 1 reaches beyond mitosis--cytokinesis, DNA damage response, and development.

Authors:  Tohru Takaki; Kristina Trenz; Vincenzo Costanzo; Mark Petronczki
Journal:  Curr Opin Cell Biol       Date:  2008-11-27       Impact factor: 8.382

8.  Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system.

Authors:  Kelly J Inglis; David Chereau; Elizabeth F Brigham; San-San Chiou; Susanne Schöbel; Normand L Frigon; Mei Yu; Russell J Caccavello; Seth Nelson; Ruth Motter; Sarah Wright; David Chian; Pamela Santiago; Ferdie Soriano; Carla Ramos; Kyle Powell; Jason M Goldstein; Michael Babcock; Ted Yednock; Frederique Bard; Guriqbal S Basi; Hing Sham; Tamie J Chilcote; Lisa McConlogue; Irene Griswold-Prenner; John P Anderson
Journal:  J Biol Chem       Date:  2008-11-12       Impact factor: 5.157

9.  Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site.

Authors:  Eric D Scheeff; Jeyanthy Eswaran; Gabor Bunkoczi; Stefan Knapp; Gerard Manning
Journal:  Structure       Date:  2009-01-14       Impact factor: 5.006

10.  Regulation of postsynaptic RapGAP SPAR by Polo-like kinase 2 and the SCFbeta-TRCP ubiquitin ligase in hippocampal neurons.

Authors:  Xiaolu L Ang; Daniel P Seeburg; Morgan Sheng; J Wade Harper
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

View more
  45 in total

1.  The Polo-like kinase PLKA in Aspergillus nidulans is not essential but plays important roles during vegetative growth and development.

Authors:  Klarita Mogilevsky; Amandeep Glory; Catherine Bachewich
Journal:  Eukaryot Cell       Date:  2011-12-02

2.  Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Authors:  Juping Yuan; Mourad Sanhaji; Andrea Krämer; Wolfgang Reindl; Matthias Hofmann; Nina-Naomi Kreis; Brigitte Zimmer; Thorsten Berg; Klaus Strebhardt
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

Review 3.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

4.  Structural analysis of the polo-box domain of human Polo-like kinase 2.

Authors:  Ju Hee Kim; Bonsu Ku; Kyung S Lee; Seung Jun Kim
Journal:  Proteins       Date:  2015-04-28

Review 5.  Understanding the Polo Kinase machine.

Authors:  V Archambault; G Lépine; D Kachaner
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

6.  Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.

Authors:  Shu-Fu Lin; Jen-Der Lin; Chun-Nan Yeh; Yu-Tung Huang; Ting-Chao Chou; Richard J Wong
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

7.  Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.

Authors:  Xue Zhi Zhao; David Hymel; Terrence R Burke
Journal:  Bioorg Med Chem       Date:  2017-02-28       Impact factor: 3.641

Review 8.  Polo-like kinase 3, hypoxic responses, and tumorigenesis.

Authors:  Dazhong Xu; Wei Dai; Cen Li
Journal:  Cell Cycle       Date:  2017-09-21       Impact factor: 4.534

9.  PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis.

Authors:  Julia Alejandra Pezuk; María Sol Brassesco; Ricardo Santos de Oliveira; Hélio Rubens Machado; Luciano Neder; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2017-03-10       Impact factor: 1.475

Review 10.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.

Authors:  Rosie Elizabeth Ann Gutteridge; Mary Ann Ndiaye; Xiaoqi Liu; Nihal Ahmad
Journal:  Mol Cancer Ther       Date:  2016-06-21       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.